Landos Biopharma (Nasdaq:LABP) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

LABP Overzicht aandelen

A clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases.

Over het bedrijf

LABP fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

De winst zal naar verwachting de komende drie jaar met gemiddeld 37.1% per jaar dalen.

Heeft geen betekenisvolle marktkapitalisatie ( $72M )

+ 1 meer risico

Landos Biopharma, Inc. Concurrenten

Milestone Pharmaceuticals

NasdaqGS:MIST

US$99.3m

VYNE Therapeutics

NasdaqCM:VYNE

US$30.5m

Rani Therapeutics Holdings

NasdaqGM:RANI

US$123.4m

Atea Pharmaceuticals

NasdaqGS:AVIR

US$281.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Landos Biopharma
Historische aandelenkoersen
Huidige aandelenkoers	US$22.93
52 Week Hoogtepunt	US$22.94
52 Week Laag	US$2.50
Bèta	0.14
11 maand verandering	2.78%
3 maanden verandering	267.47%
1 Jaar Verandering	693.43%
33 jaar verandering	-79.12%
5 jaar verandering	n/a
Verandering sinds IPO	-80.89%

Recent nieuws en updates

Recent updates

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Jun 14

Landos Biopharma (LABP) Investor Presentation - Slideshow

Jun 08

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

May 04

Rendement voor aandeelhouders

	LABP	US Pharmaceuticals	US Markt
7D	2.0%	-1.9%	-0.4%
1Y	693.4%	23.1%	34.1%

Rendement versus industrie: LABP overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 23.1 % opleverde.

Rendement versus markt: LABP overtrof de US markt, die het afgelopen jaar een rendement opleverde van 34.1 %.

Prijsvolatiliteit

Is LABP's price volatile compared to industry and market?
LABP volatility
LABP Average Weekly Movement	49.2%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van LABP is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van LABP is het afgelopen jaar gestegen van 26% naar 49%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2017	19	Greg Oakes	landosbiopharma.com

Landos Biopharma, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Landos Biopharma zich tot de beurswaarde?
LABP fundamentele statistieken
Marktkapitalisatie	US$71.68m
Inkomsten(TTM)	-US$24.80m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-2.9x

Koers/Winstverhouding

Is LABP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
LABP resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$24.80m
Inkomsten	-US$24.80m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-7.93
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde LABP op de lange termijn?

Bekijk historische prestaties en vergelijking

LABP Overzicht aandelen

Beloningen

Risicoanalyse

Landos Biopharma, Inc. Concurrenten

NasdaqGS:MIST

US$99.3m

NasdaqCM:VYNE

US$30.5m

NasdaqGM:RANI

US$123.4m

NasdaqGS:AVIR

US$281.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Landos Biopharma Files Form 15

Landos Biopharma, Inc. Announces Board and Executive Changes

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Landos Biopharma, Inc., Annual General Meeting, May 23, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

Recent updates

Landos Biopharma Files Form 15

Landos Biopharma, Inc. Announces Board and Executive Changes

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Landos Biopharma, Inc., Annual General Meeting, May 23, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

New minor risk - Share price stability

Landos Biopharma, Inc. Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis

Landos Biopharma to Present At the American College of Gastroenterology 2023 Annual Scientific Meeting

Landos Biopharma, Inc. Announces Resignation of Patrick Truesdell as Principal Accounting Officer, Patrick Truesdell Remain with Company Until November 10, 2023

Price target decreased by 52% to US$5.00

Landos Biopharma, Inc. Appoints Alka Batycky to its Board of Directors and Audit Committee

Price target decreased by 48% to US$0.55

Price target decreased by 48% to US$0.55

Price target increased by 82% to US$2.00

Landos Biopharma, Inc. announced that it expects to receive $16.690909 million in funding from Perceptive Advisors LLC

Nasdaq Grants Landos Biopharma an Additional 180-Calendar Day Compliance Period to Regain Compliance with the Minimum Bid Price Requirement

Price target decreased to US$1.10

High number of new and inexperienced directors

Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer

Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer

Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky

Landos Biopharma, Inc. Reports Positive Top-Line Results from NX-13 Phase 1B Trial

High number of new and inexperienced directors

High number of new and inexperienced directors

Landos Biopharma, Inc.(NasdaqGM:LABP) dropped from Russell 2000 Growth Index

Landos Biopharma, Inc. Names Gregory Oakes as Chief Executive Officer

Landos Biopharma Receives Non-Compliance Letter from Nasdaq

Landos Biopharma, Inc. Announces Executive Changes

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Price target decreased to US$18.82

High number of new and inexperienced directors

Roderick Wong Not Stand for Re-Election as Director of the Landos Biopharma, Inc

Price target decreased to US$18.82

Dr. Raquel Hontecillas, the Chief Scientific Officer of Landos Biopharma, Inc. Is No Longer with the Company

High number of new and inexperienced directors

Insider notifies of intention to sell stock

Insider recently sold US$456k worth of stock

Insider recently sold US$645k worth of stock

Insider recently sold US$364k worth of stock

Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Independent Director Konstantin Poukalov has left the company

Landos Biopharma’S Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation At the United European Gastroenterology Week 2021

Landos Biopharma, Inc.(NasdaqGM:LABP) dropped from Russell Microcap Value Index

Landos Biopharma, Inc. Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis Patients

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Landos Biopharma (LABP) Investor Presentation - Slideshow

Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis

Landos Biopharma Announces Positive Results from A Phase 1 Study of NX-13 in Healthy Volunteers

Landos Biopharma, Inc. has completed an IPO in the amount of $100 million.

Rendement voor aandeelhouders

Prijsvolatiliteit